ERK1/2 activity has been implicated in cancer cell apoptosis induced by various antitumor compounds, including etoposide [56], doxorubicin [57], cisplatin [58], taxol [59], miltefosine [60], and shikonin [61]. The gene discussed is MAPK3; the disease is cancer.